From the New York Times, the Wall Street Journal’s health blog, Associated Press:

A federal judge in New Jersey has ordered a drug developer to supply an experimental drug to a 16-year-old with Duchenne muscular dystrophy, even though the company says the boy is not an appropriate candidate for the drug.

The family of Jacob Gunvalson had argued that they had been misled by officials at PTC Therapeutics into believing that their son would be allowed to take part in a clinical trial. Cheri Gunvalson, Jacob’s mother, said she helped the company obtain federal grants to research the disease.

The company denied that promises had been made, and said that allowing Jacob Gunvalson access to the drug could impede research and harm the drug’s chances of getting FDA approval. The company said it plans to appeal the ruling by U.S. District Judge William J. Martini.

Earlier post here.

This entry was posted on Sunday, August 24th, 2008 at 7:04 am and is filed under NOT2BEMISSED, families, law, muscular dystrophy, research news. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.  Email This Post